MaxCyte (MXCT) Competitors

Criteo (NASDAQ:CRTO) and MaxCyte (NASDAQ:MXCT) are both computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.

Do analysts prefer CRTO or MXCT?

Criteo presently has a consensus target price of $49.89, indicating a potential upside of 32.12%. MaxCyte has a consensus target price of $9.50, indicating a potential upside of 103.86%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts clearly believe MaxCyte is more favorable than Criteo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Criteo	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
MaxCyte	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders believe in CRTO or MXCT?

94.3% of Criteo shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 1.7% of Criteo shares are owned by company insiders. Comparatively, 3.0% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Is CRTO or MXCT more profitable?

Criteo has a net margin of 4.52% compared to MaxCyte's net margin of -78.36%. Criteo's return on equity of 15.56% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Criteo	4.52%	15.56%	7.50%
MaxCyte	-78.36%	-16.00%	-13.93%

Does the media refer more to CRTO or MXCT?

In the previous week, Criteo had 2 more articles in the media than MaxCyte. MarketBeat recorded 6 mentions for Criteo and 4 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.81 beat Criteo's score of -0.01 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Criteo	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MaxCyte	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor CRTO or MXCT?

Criteo received 557 more outperform votes than MaxCyte when rated by MarketBeat users. However, 84.62% of users gave MaxCyte an outperform vote while only 66.75% of users gave Criteo an outperform vote.

Company	Underperform	Outperform
Criteo	Outperform Votes 568 66.75%	Underperform Votes 283 33.25%
MaxCyte	Outperform Votes 11 84.62%	Underperform Votes 2 15.38%

Which has more risk and volatility, CRTO or MXCT?

Criteo has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Which has preferable valuation and earnings, CRTO or MXCT?

Criteo has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Criteo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Criteo	$1.95B	1.07	$53.26M	$1.47	25.69
MaxCyte	$41.29M	11.93	-$37.92M	-$0.34	-13.71

Summary

Criteo beats MaxCyte on 11 of the 18 factors compared between the two stocks.